Arterial hypertension is a major global health burden and a well-established risk factor for chronic kidney disease (CKD). Early renal impairment in hypertensive patients often remains clinically silent and may not be detected using conventional markers such as serum creatinine alone. Identification of sensitive biomarkers capable of detecting subclinical kidney damage is essential for improving risk stratification and preventing disease progression. Objective:

This study aimed to evaluate early indicators of renal function decline in patients with arterial hypertension and to assess the association between microalbuminuria, estimated glomerular filtration rate (eGFR), and blood pressure control status.

Materials and Methods: A cross-sectional clinical study was conducted involving 162 adult patients diagnosed with essential hypertension. Clinical characteristics, duration of hypertension, blood pressure levels, and laboratory parameters including serum creatinine, eGFR (calculated using the CKD-EPI formula), and urinary microalbumin levels were assessed. Patients were stratified according to blood pressure control and duration of disease. Statistical analysis included correlation analysis, independent t-tests, and multivariate logistic regression.

Results: Microalbuminuria was detected in 34.6% of hypertensive patients, including 18.2% of individuals with controlled blood pressure. A significant negative correlation was observed between duration of hypertension and eGFR (r = –0.41, p < 0.001). Multivariate regression analysis demonstrated that duration of hypertension and systolic blood pressure were independent predictors of early renal dysfunction.

Conclusion: Microalbuminuria and subtle reductions in eGFR represent sensitive early markers of renal impairment in patients with arterial hypertension. Routine screening of these parameters may facilitate early intervention and reduce the risk of progression to chronic kidney disease.

Arterial hypertension, Chronic kidney disease, Early renal dysfunction

Bakris, G. L., & Sorrentino, M. J. (2018). Redefining hypertension—Assessing the new blood-pressure guidelines. New England Journal of Medicine, 378(6), 497–499. https://doi.org/10.1056/NEJMp1716193

Böhm, M., Schumacher, H., Teo, K. K., Lonn, E. M., Mahfoud, F., Mann, J. F. E., … Yusuf, S. (2017). Achieved blood pressure and cardiovascular outcomes in high-risk patients: Results from ONTARGET and TRANSCEND trials. The Lancet, 389(10085), 2226–2237. https://doi.org/10.1016/S0140-6736(17)30754-7

Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., … Taler, S. J. (2021). Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International, 99(3), 559–569. https://doi.org/10.1016/j.kint.2020.10.026

Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F. E., … Wen, C. P. (2013). Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. The Lancet, 382(9889), 339–352. https://doi.org/10.1016/S0140-6736(13)60595-4

Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015). Obesity-induced hypertension: Interaction of neurohumoral and renal mechanisms. Circulation Research, 116(6), 991–1006. https://doi.org/10.1161/CIRCRESAHA.116.305697

KDIGO. (2012). KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements, 3(1), 1–150.

Ku, E., Lee, B. J., Wei, J., & Weir, M. R. (2019). Hypertension in CKD: Core curriculum 2019. American Journal of Kidney Diseases, 74(1), 120–131. https://doi.org/10.1053/j.ajkd.2018.12.044

Matsushita, K., van der Velde, M., Astor, B. C., Woodward, M., Levey, A. S., de Jong, P. E., … Gansevoort, R. T. (2010). Association of estimated glomerular filtration rate and albuminuria with mortality and renal failure. The Lancet, 375(9731), 2073–2081. https://doi.org/10.1016/S0140-6736(10)60674-5

Muntner, P., Whelton, P. K., Woodward, M., Carey, R. M., & Reynolds, K. (2018). Clinical outcomes in hypertensive patients according to blood pressure control. Hypertension, 71(3), 568–574.

Ruilope, L. M., Segura, J., & Praga, M. (2001). Microalbuminuria in essential hypertension: Pathophysiology and clinical implications. Kidney International, 59(1), 157–165.

Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., … Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13–e115. https://doi.org/10.1161/HYP.0000000000000065

Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. L., Castro, A. F., Feldman, H. I., … Coresh, J. (2009). A new equation to estimate glomerular filtration rate. Annals of Internal Medicine, 150(9), 604–612.

Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., … Levey, A. S. (2007). Prevalence of chronic kidney disease in the United States. JAMA, 298(17), 2038–2047.

Taal, M. W., & Brenner, B. M. (2006). Renoprotective benefits of RAS inhibition. Kidney International, 69(8), 1343–1352.

Pontremoli, R., & Leoncini, G. (2007). Microalbuminuria, cardiovascular, and renal risk in primary hypertension. Journal of the American Society of Nephrology, 18(Suppl 1), S3–S9.